Table 4.
Molecule | Target | Mechanism | Condition | Clinical trial |
---|---|---|---|---|
AZD3965 | Lactate transporters | Inhibits MCT1/2 | Malignant tumor | Phase I Trial |
α-Cyano-4-hydroxycinnamate | Lactate transporters | Inhibits MCT1/2 | Hyperglycolytic malignancies | N/A |
AR-C155858 | Lactate transporters | Inhibits MCT1/2 | Hyperglycolytic malignancies | N/A |
Syrosingopine | Lactate transporters | Inhibits MCT1/4 | Malignant tumor | N/A |
Meplazumab | CD147 | Inhibits the distribution of MCT1/4 on cell membrane | Malignant tumor, COVID-19 | Phase I Trial |
Stiripentol | LDH | Inhibits LDH | Epilepsy, Dravet Syndrome | Approved by FDA |
Galloflavin | LDH | Binds the free enzyme | Malignant tumor | N/A |
N-hydroxyindoles | LDH | Compete with pyruvate and NADH | N/A | N/A |
AT-101 (gossypol) | LDH | Inhibits LDH | Malignant tumor | Phase II Trial |
FX-11 | LDH | Inhibits LDH-A | Pancreatic cancer | N/A |
GSK2837808A | LDH | Inhibits LDH-A | N/A | N/A |
Vitamin C | LDH | Inhibits LDH-A | Breast cancer | N/A |
2-DG | HK | Inhibits glycolysis by competing with glucose | Malignant tumor | Dose Escalation Trial, Phase I/II Trial |
DCA | PDK | Increases glucose uptake into mitochondria | Malignant tumor, Lactic acidosis | Phase I/II Trial |
Lonidamine | HK | Inhibits glycolysis | Malignant tumor | Phase II Trial |
Notes: N/A not available